Mer­ri­mack CEO, CFO bow out, months af­ter last clin­i­cal drug fiz­zles

Two months ago, Mer­ri­mack was forced to aban­don its last drug in clin­i­cal tri­als, af­ter an ear­ly-stage study showed that treat­ment with the drug, MM-310, was cu­mu­la­tive­ly tox­ic to pa­tients, de­spite tri­al pro­to­col amend­ments. On Mon­day, the ex-Sanofi ex­ec­u­tive the Cam­bridge, Mass­a­chu­setts-based com­pa­ny ush­ered in 2017 to re­vive its for­tunes de­part­ed.

In 2015, Mer­ri­mack $MACK se­cured FDA ap­proval for its pan­cre­at­ic can­cer drug — Onivyde, which had a dis­ap­point­ing de­but. It was sold to Ipsen in 2017, in par­al­lel to a re­struc­tur­ing, which cul­mi­nat­ed in a new CEO — Richard Pe­ters — a slim­mer work­force and three pipeline prospects: MM-141, MM-121 and MM-310. Each of these drugs has now been rel­e­gat­ed to the scrap heap.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.